Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study
Cancer Science · 03.11.2026
DOI: 10.1111/cas.70561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 03.11.2026. Verfasst von Kuniko Sunami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Japan Inc, Pfizer Japan.
Abstract (Originalsprache)
Comprehensive genomic profiling (CGP) is standard for advanced solid tumors. Evidence reporting its real‐world utilization pattern and time course for guided therapy is limited. This retrospective study in Japan assessed the real‐world utility of CGP tests for advanced or metastatic solid tumors using data from the C‐CAT registry from June 1, 2019, to August 23, 2025. We evaluated the proportion of patients who received genomically matched therapy with expert panel (EP) recommendation and their overall survival (OS) compared with patients who did not receive genomically matched therapy. The study population comprised 89,552 patients who underwent CGP: median age 64.0 (interquartile range: 54.0–72.0) years, with pancreatic cancer (13,827; 15.4%) and colorectal cancer (11,322; 12.6%) the most common tumor types. System‐generated matched treatment options presented as reference information during EP review were identified in 80,185, of whom 77,337 (96.4%) received EP review, 37,245 (46.4%) were offered new therapeutic recommendations, and 7124 (8.9%) initiated EP‐recommended therapies. Among 2049 patients who were newly identified with companion diagnostic (CDx)‐related druggable alterations, 319 (15.6%) received matched therapies. Patients receiving matched therapies experienced longer OS compared with others in the overall cohort (median: 538 days vs. 356 days) and across cancer types. OS varied by the final treatment line before CGP testing, with earlier lines associated with longer survival in biliary tract, ovarian, pancreatic, and thyroid cancers. These findings highlight the need for timely CGP implementation to maximize the impact of precision oncology. Trial Registration: Japan Registry of Clinical Trials identifier: jRCT1030250365
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
- Real World Evidence, Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan.
- ONC Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
ORCID-Profile: Kuniko Sunami, Masashi Mikami
Förderung
- Pfizer Japan Inc
- Pfizer Japan
Zitieren
APA
Sunami, K., Mikami, M., Tanaka, M., Aoyagi, S. S., & Togo, K. (2026). Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study. Cancer Science. https://doi.org/10.1111/cas.70561
Vancouver
Sunami K, Mikami M, Tanaka M, Aoyagi SS, Togo K. Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study. Cancer Science. 2026. doi:10.1111/cas.70561
BibTeX
@article{Sunami2026,
author = {Sunami, Kuniko and Mikami, Masashi and Tanaka, Masayuki and Aoyagi, Sona-Sanae and Togo, Kanae},
title = {Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70561}
}
EUVIMED